Structure-activity relationship study on the binding of PBDEs with thyroxine transport proteins

Environmental Toxicology and Chemistry

Volumn 30, Issue 11, 2011, Pages 2431-2439

  Yang, Weihua ^a   Shen, Shide ^b   Mu, Lailong ^a   Yu, Hongxia ^c  

^a JIANGSU NORMAL UNIVERSITY   (China)

^b Xuzhou Institute of Architectural Technology   (China)

^c NANJING UNIVERSITY   (China)

Author keywords

Comparative molecular similarity indices analysis; Ligand receptor interaction mechanism; Surflex dock; Thyroid hormone disrupting activity; Transthyretin

Indexed keywords

COMPARATIVE-MOLECULAR-SIMILARITY-INDICES ANALYSIS; LIGAND-RECEPTOR INTERACTIONS; SURFLEX-DOCK; THYROID HORMONE-DISRUPTING ACTIVITY; TRANSTHYRETIN;

AMINO ACIDS; BINDING ENERGY; CHEMICAL ENGINEERING; COMPUTATIONAL CHEMISTRY; ENZYME INHIBITION; ETHERS; HYDROGEN; HYDROGEN BONDS; MOLECULAR MODELING; ORGANIC POLLUTANTS; POLYACRYLATES;

THREE DIMENSIONAL;

ALANINE; ASPARAGINE; ASPARTIC ACID; HYDROGEN; HYDROXYL GROUP; POLYBROMINATED DIPHENYL ETHER; PREALBUMIN;

AMINO ACID; CHEMICAL BONDING; HORMONE; MODEL VALIDATION; MOLECULAR ANALYSIS; NUMERICAL MODEL; PBDE; PROTEIN;

ARTICLE; BINDING AFFINITY; BINDING KINETICS; HUMAN; HYDROGEN BOND; HYDROXYLATION; MOLECULAR DOCKING; MOLECULAR INTERACTION; MOLECULAR MODEL; PREDICTION; PRIORITY JOURNAL; PROTEIN BINDING; QUANTITATIVE ANALYSIS; STRUCTURE ACTIVITY RELATION;

HALOGENATED DIPHENYL ETHERS; HUMANS; HYDROGEN BONDING; MODELS, CHEMICAL; MOLECULAR CONFORMATION; PROTEIN BINDING; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; THYROXINE-BINDING PROTEINS;

RUMEX;

EID: 80054093702     PISSN: 07307268     EISSN: 15528618     Source Type: Journal    
DOI: 10.1002/etc.645     Document Type: Article

References (28)

1. Schecter A, Vuk MP, Papke O, Ryan JJ, Birnbaum L, Rosen R. 2003. Polybrominated diphenyl ethers (PBDEs) in U.S. mothers' milk. Environ Health Perspect 111: 1723-1729.
2. Schecter A, Papke O, Harris TR, Tung KC. 2006. Partitioning of polybrominated diphenyl ether (PBDE) congeners in human blood and milk. Toxicol Environ Chem 88: 319-324.
3. Johnson-Restrepo B, Kannan K, Rapaport DP, Rodan BD. 2005. Polybrominated diphenyl ethers and polychlorinated biphenyls in human adipose tissue from New York. Environ Sci Technol 39: 5177-5182.
4. Mercado-Feliciano M, Bigsby RM. 2008. Hydroxylated metabolites of the polybrominated diphenyl ether mixture DE-71 are weak estrogen receptor-alpha ligands. Environ Health Perspect 116: 1315-1321.
5. Wan Y, Wiseman S, Chang H, Zhang XW, Jones PD, Hecker M, Kannan K, Tanabe S, Hu JY, Lam MHW, Giesy JP. 2009. Origin of hydroxylated brominated diphenyl ethers: natural compounds or man-made flame retardants? Environ Sci Technol 43: 7536-7542.
6. Athanasiadou M, Cuadra SN, Marsh G, Bergman A, Jakobsson K. 2008. Polybrominated diphenyl ethers (PBDEs) and bioaccumulative hydroxylated PBDE metabolites in young humans from Managua, Nicaragua. Environ Health Perspect 116: 400-408.
7. Cantón RF, Scholten DEA, Marsh G, De Jong PC, van den Berg M. 2008. Inhibition of human placental aromatase activity by hydroxylated polybrominated diphenyl ethers (OH-PBDEs). Toxicol Appl Pharmacol 227: 68-75.
8. Lacorte S, Ikonomou MG. 2009. Occurrence and congener specific profiles of polybrominated diphenyl ethers and their hydroxylated and methoxylated derivatives in breast milk from Catalonia. Chemosphere 74: 412-420.
9. Qiu XH, Bigsby RM, Hites RA. 2009. Hydroxylated metabolites of polybrominated diphenyl ethers in human blood samples from the United States. Environ Health Perspect 117: 93-98.
10. He Y, Murphy MB, Yu RMK, Lam MHW, Hecker M, Giesy JP, Wu RSS, Lam PKS. 2008. Effects of 20 PBDE metabolites on steroidogenesis in the H295R cell line. Toxicol Lett 176: 230-238.
11. Lagalante AF, Oswald TD, Calvosa FC. 2009. Polybrominated diphenyl ether (PBDE) levels in dust from previously owned automobiles at United States dealerships. Environ Int 35: 539-544.
12. McDonald TA. 2002. A perspective on the potential health risks of PBDEs. Chemosphere 46: 745-755.
13. Meerts IATM, van Zanden JJ, Luijks EAC, van Leeuwen-Bol I, Marsh G, Jakobsson E, Bergman Å, Brouwer A. 2000. Potent competitive interactions of some brominated flame retardants and related compounds with human transthyretin in vitro. Toxicol Sci 56: 95-104.
14. Hamers T, Kamstra JH, Sonneveld E, Murk AJ, Kester MHA, Andersson PL, Legler J, Brouwer A. 2006. In vitro profiling of the endocrine-disrupting potency of brominated flame retardants. Toxicol Sci 92: 157-173.
15. Legler J, Brouwer A. 2003. Are brominated flame retardants endocrine disruptors? Environ Int 29: 879-885.
16. Hamers T, Kamstra JH, Sonneveld E, Murk AJ, Visser TJ, Van Velzen MJM, Brouwer A, Bergman Å. 2008. Biotransformation of brominated flame retardants into potentially endocrine-disrupting metabolites, with special attention to 2, 2', 4, 4'-tetrabromodiphenyl ether (BDE-47). Mol Nutr Food Res 52: 284-298.
17. Papa E, Kovarich S, Gramatica P. 2010. QSAR modeling and prediction of the endocrine-disrupting potencies of brominated flame retardants. Chem Res Toxicol 23: 946-954.
18. Kovarich S, Papa E, Gramatica P. 2011. QSAR classification models for the prediction of endocrine disrupting activity of brominated flame retardants. J Hazard Mater 190: 106-112.
19. Martinez L, Polikarpov I, Skaf MS. 2008. Only subtle protein conformational adaptations are required for ligand binding to thyroid hormone receptors: simulations using a novel multipoint steered molecular dynamics approach. J Phys Chem B 112: 10741-10751.
20. Sippl W. 2002. Development of biologically active compounds by combining 3D QSAR and structure-based design methods. J Comput Aided Mol Des 16: 825-830.
21. Soderholm AA, Lehtovuori PT, Nyronen TH. 2005. Three-dimensional structure-activity relationships of nonsteroidal ligands in complex with androgen receptor ligand-binding domain. J Med Chem 48: 917-925.
22. Harju M, Hamers T, Kamstra JH, Sonneveld E, Boon JP, Tysklind M, Andersson PL. 2007. Quantitative structure-activity relationship modeling on in vitro endocrine effects and metabolic stability involving 26 selected brominated flame retardants. Environ Toxicol Chem 26: 816-826.
23. Kubinyi H, Hamprecht FA, Mietzner T. 1998. Three-dimensional quantitative similarity-activity relationships (3D QSAR) from SEAL similarity matrices. J Med Chem 41: 2553-2564.
24. Liu HX, Papa E, Gramatica P. 2006. QSAR prediction of estrogen activity for a large set of diverse chemicals under the guidance of OECD principles. Chem Res Toxicol 19: 1540-1548.
25. Cross JB, Thompson DC, Rai BK, Christian Baber J, Fan KY, Hu YB, Humblet C. 2009. Comparison of several molecular docking programs: Pose prediction and virtual screening accuracy. J Chem Inf Model 49: 1455-1474.
26. Golbraikh A, Tropsha A. 2002. Beware of q2. J Mol Graph Model 20: 269-276.
27. Fang H, Tong WD, Welsh WJ, Sheehan DM. 2003. QSAR models in receptor-mediated effects: the nuclear receptor superfamily. J Mol Struct (Theochem) 622: 113-125.
28. Ghosh M, Meerts IA, Cook A, Bergman Å, Brouwer A, Johnson LN. 2000. Structure of human transthyretin complexed with bromophenols: A new mode of binding. Acta Crystallogr D Biol Crystallogr 56: 1085-1095.